Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks

Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks

293429

Orladeyo Approved in EU as 1st Oral Treatment to Prevent HAE Attacks

The European Commission has approved BioCryst Pharmaceuticals’ Orladeyo (berotralstat) as the first oral, daily therapy to prevent swelling attacks in adults and adolescents, ages 12 and older, with hereditary angioedema (HAE). An oral preventive therapy should be easier to take than standard under-the-skin and into-the-vein alternatives, and as such is expected to improve patients’ quality of life and independence. “Most European HAE patients today treat their disease with on-demand therapy or androgens and we believe the approval…

You must be logged in to read/download the full post.